A Combined Positive Score subgroup in training cohort

B Molecular subgroup in training cohort

C Number of lines of prior therapies in the advanced setting subgroup in training cohort

D Visceral metastasis subgroup in training cohort

E Number of metastatic sites subgroup in training cohort

F Combined immunotherapy regimen subgroup in training cohort

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material which has been supplied by the author(s) J Immunother Cancer
doi: 10.1136/jitc-2022-006514:
e006514. 11 2023; J Immunother Cancer, et al. Zhao J